Valvular heart diseases in the developing world: Developmental biology takes center stage

Journal of Heart Valve Disease

Volumn 21, Issue 2, 2012, Pages 234-240

  Farrar, Emily J ^a   Butcher, Jonathan T ^a  

^a School of Chemical and Molecular Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CANDESARTAN; CHONDROMODULIN 1; CYTOKINE RECEPTOR ANTAGONIST; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; DEVELOPING COUNTRY; DEVELOPMENTAL BIOLOGY; DISEASE SEVERITY; EMBRYO DEVELOPMENT; ENDOCARDIUM; EPITHELIAL MESENCHYMAL TRANSITION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VALVE; HEART VALVE REPLACEMENT; HUMAN; INCIDENCE; MORTALITY; MYOFIBROBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE ENGINEERED HEART VALVE; TISSUE ENGINEERING; TRANSLATIONAL RESEARCH; UGANDA; VALVULAR HEART DISEASE; PRENATAL DEVELOPMENT; REVIEW;

DEVELOPING COUNTRIES; DEVELOPMENTAL BIOLOGY; ENDOMYOCARDIAL FIBROSIS; HEART VALVE DISEASES; HUMANS; RHEUMATIC HEART DISEASE;

EID: 84862985792     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J 2004;148:1-4
2. Mathers C, Fat DM, Boerma J. The global burden of disease: 2004 update. WHO, 2008
3. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007;93:1176-1183
4. Mutazind T. Survival after first presentation with endomyocardial fibrosis. Br Heart J 1972;34:403-407
5. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: Genetics and pathogenesis. Scand J Immunol 2007;66:199-207
6. Mayosi B, Robertson K, Volmink J, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J 2006;96:246
7. Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Eng J Med 2008;359:43-49
8. Yusuf S, Reddy S, Ounpuu S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753
9. Moran M, Guzman J, Ropars AL, et al. Neglected disease research and development: How much are we really spending? PLoS Med 2009;6:0137-0146
10. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-69411.
11. Wayne AR, Schlant RC, Fuster V. Hurst's The Heart, Arteries and Veins. McGraw-Hill, Health Professions Division, New York, 1998
12. Drakensberg Declaration on the Control of Rheumatic Fever and Rheumatic Heart Disease in the World, 2011
13. Watkins DA, Zuhlke LJ, Engel ME, Mayosi BM. Rheumatic fever: Neglected again. Science 2009;324:37
14. Paar J, Berrios NM, Rose JD, et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Cardiol 2010;105:809-814
15. Rheumatic Fever and Rheumatic Heart Disease: Report of a WHO Expert Consultation, Geneva, 2004
16. Freers J, MayanjaKizza H, Ziegler JL, Rutakingirwa M. Echocardiographic diagnosis of heart disease in Uganda. Trop Doct 1996;26:125-128
17. Anabwani GM, Bonhoeffer P. Prevalence of heart disease in school children in rural Kenya using colour-flow echocardiography. East Afr Med J 1996;73:215-217
18. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007;357:470-476
19. Paar JA, Berrios NM, Rose JD, et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Cardiol 2010;105:1809-1814
20. Sadiq M, Islam K, Abid R, et al. Prevalence of rheumatic heart disease in school children of urban Lahore. Heart 2009;95:353-357
21. Ansa VO, Ekott JU, Bassey EO. Profile and outcome of cardiovascular admissions at the university of Uyo Teaching Hospital, Uyo: A five year review. Niger J Clin Pract 2008;11:22-24
22. American Heart Association. Heart Attack and Angina Statistics, 2011
23. Dajani AS, Ayoub E, Bierman FZ, et al. Guidelines for the Diagnosis of Rheumatic Fever: Jones Criteria, 1992 Update. JAMA 1992;268:2069-2073
24. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511
25. Oli K, Asmera J. Rheumatic heart disease in Ethiopia: Could it be more malignant? Ethiop Med J 2004;421-428
26. Chin TK, Chin EM, Siddiqui T, Sundell AK. Rheumatic Heart Disease [Internet], 2010. Available at: http://emedicine.medscape.com/article/891897- overview
27. Rheumatic Fever [Internet]. Available at: www.ourmed.org
28. Braun M. General and Systemic Histopathology: Rheumatic Valvulitis [Internet]. Available at: medsci.indiana.edu
29. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian FL, Rahimtoola S. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: Final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000;36:1152-1158
30. Zilla P, Brink J, Human P, Bezuidenhout D. Prosthetic heart valves: Catering for the few. Biomaterials 2008;29:385-406
31. Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis: Still a mystery after 60 years. PLoS Negl Trop Dis 2008;2:e97
32. Connor DH, Somers K, Hutt MSR, Manion WC, Darbela PG. Endomyocardial fibrosis in Uganda (Davies disease): An epidemiologic clinical and pathologic study. Am Heart J 1967;74:687-709
33. Mocumbi AO, Yacoub S, Yacoub MH. Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: Myocardial disease. Heart 2008;94:384-390
34. Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-β. J Clin Invest 2010;120:3520-3529
35. Burke AP. Pathology of infectious endocarditis. Medscape Reference, 2011. Web 10th July, 2011
36. Niu JL, Azfer A, Rogers LM, Wang XH, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc Res 2007;73;549-559
37. Davies JNP, Ball JD. The pathology of endomyocardial fibrosis in Uganda. Br Heart J 1955;17:337-359
38. .Wright IG, Walker IA, Yacoub MH. Specialist surgery in the developing world: Luxury or necessity? Anaesthesia 2007;62(Suppl.):184-189
39. Butcher JT, Markwald RR. Valvulogenesis: The moving target. Philos Trans R Soc London (Biol) 2007;362:1489-1503
40. Hakuno D, Kimura N, Yoshioka M, Fukuda K. Molecular mechanisms underlying the onset of degenerative aortic valve disease. J Mol Med 2009;87:17-24
41. Yoshioka M, Yuasa S, Matsumura K, Kimura K. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nature Med 2006;12:1151-1159
42. Markwald RR, Norris RA, Moreno-Rodriguez R, Levine RA. Developmental basis of adult cardiovascular diseases: Valvular heart diseases. Ann N Y Acad Sci 2010;1188:177-183
43. Shworak NW. Angiogenic modulators in valve development and disease: Does valvular disease recapitulate developmental signaling pathways? Curr Opin Cardiol 2004;19:140-146
44. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Med 2007;13:952-961
45. Boyer AS, Ayerinskas II, Vincent EB, McKinney LA, Weeks DL, Runyan RB. TGF beta 2 and TGF beta 3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol 1999;208:530-545
46. Brown CB, Boyer AS, Runyan RB, Barnett JV. Antibodies to the type II TGF beta receptor block cell activation and migration during atrioventricular cushion transformation in the heart. Dev Biol 1996;174:248-257
47. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999;283:2080-2082
48. Chen K, Mehta JL, Li DY, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004;95:1167-1173
49. Goumans MJ, van Zonneveld AJ, ten Dijke P. Transforming growth factor beta-induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis? Trends Cardiovasc Med 2008;18:293-298
50. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 2009;19:247-252
51. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95
52. Chu PY, Mariani J, Finch S, et al. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 2010;176:1735-1742
53. Haudek SB, Cheng J, Du J, et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010;49:499-507
54. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: Multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004;19:517-525
55. Widyantoro B, Emoto N, Nakayama K. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010;121:2379-2380.
56. Kim L, Kim DK, Yang WI, et al. Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease. J Korean Med Sci 2008;23:41-48
57. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci 2003;8:533-543
58. Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol 2010;106:713-719
59. Hinton RB, Lincoln J, Deutsch GH, et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 2006;98:1431-1438
60. Lewin M, Otto C. The bicuspid aortic valve: Adverse outcomes from infancy to old age. Circulation 2005;111:832-834
61. Weber B, Scherman J, Emmert MY, et al. Injectable living marrow stromal cell-based autologous tissue-engineered heart valves: First experiences with a one-step intervention in primates. Eur Heart J 2011;32:2830-2840